Prior to joining Exelixis, I was an investment banker at Goldman Sachs, focusing on M&A and corporate finance.
Frank Karbe
Chief Financial Officer, Exelixis
Prior to joining Exelixis, I was an investment banker at Goldman Sachs, focusing on M&A and corporate finance. In my last three years at Goldman, I was part of the healthcare team in San Francisco. I spent the majority of my time with clients in the biotechnology industry, including Exelixis. I was especially excited about the opportunity to join the Exelixis team because I believe in the company's potential to innovate first- or best-in-class drugs, and to become a world-class biopharmaceutical company. Very few people, certainly at my age, get the opportunity to be part of an executive team that has a shot at building one of the leading companies in its industry.
Given that Exelixis has taken an unusual approach for a pre-commercial biotech, we have an uncommon appetite for capital. Over the past four years, Exelixis has raised close to $1 billion in new funding—a majority of which has come from nondilutive sources. We have complemented our leadership in drug discovery with leadership in raising capital and business development.
Scientific innovation will always be critical for success in the biotech and pharma industries. But there cannot be scientific progress without adequate funding, and this funding will not be available if our industry is not rewarded for its innovations.
Efforts to reform US healthcare policy must address the need to reward innovation; we have to ensure that biotech and pharma products—and the companies that make them—are seen as solutions to the healthcare challenges we face, not as the problem. Innovative strategies for financing clinical candidates, accessing capital, monetizing assets, and partnerships are all critical to "feeding the beast."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.